apolipoprotein c-ii cofactor for lipoprotein lipase Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD | Current Atherosclerosis Reports Frontiers | Using Synthetic ApoC-II

Despite the absence of pGSH1 -driven URA3 expression in the pURA3-URA3 strain, cultivation in the presence of 5-FOA again gave a significant, ~ 50% increase in GSH level (Figure S4B)

A 10-year follow-up study demonstrated that the total incidence of neoplasms was higher among IVF-conceived children (1.5/1000 person-years) than among naturally conceived children (0.59/1000 person-years

Most patients begin noticing subtle but consistent improvements within 3 to 6 weeks

FOXO4-DRI is a D-retro-inverso peptide built from a FOXO4 fragment that binds p53, joined to a cell-penetrating sequence, with a molecular weight near 4.8 kDa